SLC2A1 and glioblastoma: A Glioblastoma study has proposed small molecular inhibitors targeting TUBB4 as adjuvant therapy in Glioblastoma treatment, as they observed a fall in GLUT1 expression, a protein essential for Glioblastoma stem cell survival.